Kyle Michael Wool Buys 3,559 Shares of AIkido Pharma Inc. (NASDAQ:AIKI) Stock

AIkido Pharma Inc. (NASDAQ:AIKIGet Rating) Director Kyle Michael Wool purchased 3,559 shares of the stock in a transaction dated Friday, September 16th. The shares were purchased at an average price of $6.54 per share, with a total value of $23,275.86. Following the completion of the transaction, the director now owns 230,281 shares of the company’s stock, valued at $1,506,037.74. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.

AIkido Pharma Stock Up 1.7 %

AIKI opened at $7.03 on Wednesday. AIkido Pharma Inc. has a 52 week low of $4.30 and a 52 week high of $16.58. The business has a fifty day simple moving average of $6.09 and a 200-day simple moving average of $6.10. The firm has a market cap of $36.89 million, a P/E ratio of -2.59 and a beta of 1.33.

Institutional Inflows and Outflows

An institutional investor recently raised its position in AIkido Pharma stock. Jane Street Group LLC raised its position in shares of AIkido Pharma Inc. (NASDAQ:AIKIGet Rating) by 247.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 100,096 shares of the business services provider’s stock after buying an additional 71,284 shares during the period. Jane Street Group LLC owned about 0.11% of AIkido Pharma worth $45,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 13.95% of the company’s stock.

AIkido Pharma Company Profile

(Get Rating)

AIkido Pharma Inc, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.

Featured Articles

Receive News & Ratings for AIkido Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIkido Pharma and related companies with's FREE daily email newsletter.